Study title:
(Analysis of cases allowed to cease erythromycin therapy for diffuse panbronchiolitis comparative study between patients with cessation of the therapy and patients continuing the therapy). Shirai R, Abe K, Yoshinaga M, Ishimatsu Y, Matsubara Y, Kawakami K, Iida K, Fujii T, Kawamoto S, Kaseda M, Kadota J, Kohno S. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, Nov 1997, vol. 71, no. 11, p. 1155 61
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Bacterial Infections and Mycoses [C01]
|
Brands: Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: ERYTHROMYCIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|